Mandrik, Olena http://orcid.org/0000-0003-3755-3031
Hahn, Anne I.
Catto, James W. F.
Zauber, Ann G.
Cumberbatch, Marcus
Chilcott, James
Funding for this research was provided by:
Yorkshire Cancer Research (RA/2019/R1/004)
Article History
Accepted: 13 February 2023
First Online: 8 March 2023
Declarations
:
: This study was supported by the Yorkshire Cancer Research UK (Grant number RA/2019/R1/004). James W.F. Catto is funded by an NIHR Research Professorship.
: James W.F. Catto reported receiving reimbursement for consultancy from AstraZeneca, Ferring, Roche and Janssen; speaker fees from Bristol Myers Squibb, Merck Sharp & Dohme, Janssen, Astellas, Nucleix and Roche; honoraria for membership in advisory boards from Ferring, Roche, Gilead, Photocure, Bristol Myers Squibb, QED Therapeutics and Janssen; and research funding from Roche. Olena Mandrik, Anne I. Hahn, Ann G. Zauber, Marcus Cumberbatch and James Chilcott have no conflicts of interest that are directly relevant to the content of this article.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: The work reported in the paper has been performed by the authors, unless clearly specified in the text. Conceptualization: OM, AIH, AGZ, JC; methodology: OM, JC; analysis and interpretation of data: OM, AIH; drafting of the manuscript: OM, AIH, JWFC, AGZ, MC, JC; funding acquisition: JWFC, JC.